Indirect costs associated with metastatic breast cancer.
Yin Wan(Pharmerit (United States)), Lee S. Schwartzberg(Renown Health), Xīn Gào(Qingdao University), Zhixiao Wang(Eisai (United States)), Sonam Mehta(Pharmerit (United States)), Claudio Faria(Eisai (United States))
Cited by 2
Related Papers
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k
Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study
|Journal of Clinical Oncology|2008|623
NCCN Guidelines Insights: Breast Cancer, Version 1.2017
|Journal of the National Comprehensive Cancer Network|2017|544